CONVINCE: Colchicine for prevention of vascular inflammation in non-cardioembolic stroke

Clinical Practice Research Unit (CPRU)

CONVINCE is a randomised clinical trial of low dose colchicine for secondary prevention after stroke.

Accumulating evidence indicates that inflammation is of key importance to the destabilisation of atherosclerotic plaques. Colchicine shows anti-inflammatory effects mediated through a reduction in macrophage/monocyte activity leading to reduction in inflammatory changes which may destabilise arterial plaques and result in thromboembolism from the plaques.

The CONVINCE study is randomising participants post non-cardioembolic stoke or high-risk TIA to receive usual care or usual care plus 500 micrograms of colchicine per day. The study aims to find if adding daily low-dose colchicine to usual care shows a reduction in recurrence of non-fatal ischaemic stroke, TIA, myocardial infarction, hospitalisation for unstable angina, cardiac arrest and vascular death after ischaemic stroke between the two arms of the study.

Expertise and Subject area

Project Lead/Contact

  • Chief Investigator Global: Professor Peter Kelley, University College Dublin Clinical Research Centre, Mater Misericordiae University Hospital, Dublin.
  • Chief Investigator UK: Dr Chris Price, Clinical Reader, Institute of Neuroscience, Newcastle University UK.
  • Lancashire Clinical Trials Unit Contact: Mrs Denise Forshaw, Principal Trial Manager,, 01772 893629.
External Links

Project Staff

  • Miss Alexandra Haig - Senior Trials Assistant
  • Miss Alison Gibbon - Trials Assistant
  • Miss Carole Bruce - Data Coordinator

Clients or Funders

Health Research Board of Ireland


2016 - 2021